Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder

Abstract

An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol.

1 . A protective agent for a keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder comprising glucosylglycerol as an active ingredient. 
     
     
         2 . The protective agent for the keratoconjunctiva or the suppressive agent for a keratoconjunctival disorder according to  claim 1 , wherein the agent is used for protecting the keratoconjunctiva against an endogenous disease of Sjogren's syndrome, Stevens-Johnson syndrome, or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery, a drug, an injury, or the wearing of a contact lens or suppressing the keratoconjunctival disorder due to said diseases. 
     
     
         3 . Use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder. 
     
     
         4 . The use according to  claim 3 , wherein the protection of the keratoconjunctiva or the suppression of the a keratoconjunctival disorder is protection of the keratoconjunctiva against an endogenous disease of Sjogren's syndrome, Stevens-Johnson syndrome, or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery, a drug, an injury, or the wearing of a contact lens or the suppression of the keratoconjunctival disorder due to said diseases. 
     
     
         5 . A method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol. 
     
     
         6 . The method according to  claim 5  for protecting the keratoconjunctiva against an endogenous disease of Sjogren's syndrome, Stevens-Johnson syndrome, or dry eye syndrome (dry eye) or an exogenous disease due to postsurgery, a drug, an injury, or the wearing of a contact lens or suppressing the keratoconjunctival disorder due to said diseases.